StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Vytorin by Quarter

Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — International sales ($M) ($M)

QuarterlyAnnual

Merck Vytorin: $38M in Q1 2021, down 24.0% from a year earlier. No newer figure appears in the documents we track.

Latest, Q1 2021
38
Period ended Mar 31, 2021
Change on a year earlier
-24.0%
50 in Q1 2020
History
18 quarters
Since Q4 2016
Sources
14
Documents cited below

Where the Q1 2021 figure comes from

“|| Vytorin | 41 | 53 | -23 | 2 | 3 | -29 | 38 | 50 | -23”

Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — International sales ($M) ($M)Year on yearSource
Q1 2021Mar 31, 202138-24.0%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 202041-16.3%Form 10-K (filed 2021-02-25) ↗
Q3 2020Sep 30, 202044-15.4%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 202037-49.3%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 202050-46.8%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 201949-41.7%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 201952-43.5%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 201973-52.0%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 201994-40.5%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2018Dec 31, 201884-52.3%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 201892-37.8%Form 10-Q (filed 2019-11-05) ↗
Q2 2018Jun 30, 20181520.0%Form 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2018Mar 31, 2018158+4.6%Form 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2017Dec 31, 2017176+5.4%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 2017148–Form 10-Q (filed 2018-11-06) ↗
Q2 2017Jun 30, 2017152–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗

Breakdown

What makes up vytorin

Cite this data

StockData. (2026). Merck Vytorin ($M), quarterly Q4 2016–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vytorin-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.